Interestingly, the drugs in development are improved versions of methylene blue, discussed previously in this forum.

"TauRx’s pipeline of therapeutics includes a range of compounds that have arisen from research, preclinical and clinical investigations the Company first performed using rember™. rember™ is TauRx’s ultrapure Tau Aggregation Inhibitor (TAI), with patents pending, a version of methylene blue (methylthionine chloride), a comparatively crude and poorly tolerated compound previously used to treat a variety of conditions. TauRx has discovered and is developing alternative forms of the same active moiety present in rember™ that have been chemically optimized to afford enhanced tolerability and bioavailability, enabling their use at higher doses than rember™. TauRx’s TAIs are backed by a robust patent estate.


TauRx’s lead “second generation” TAI has the potential to achieve greater clinical efficacy than the striking effects already shown with rember™. Delivering the same active moiety in the blood as rember™, the clinical tolerability profile of LMTX, one of TauRx’s second generation TAIs, is currently being investigated clinically in trials conducted under an open US IND. TauRx is now preparing to advance LMTX into pivotal international phase 3 trials in mild and moderate AD and related neurodegenerative diseases."